TABLE 1.
Prevalence of indicators of asthma, rhinoconjunctivitis and eczema in centres grouped by GNI. Global Asthma Network Phase I (2015–2020)
| Age group | GNI | Years | Centres, n | Total, n | Current wheeze | Asthma ever | Severe asthma symptoms | Current rhinoconjunctivitis symptoms | Hay fever ever | Symptoms of severe rhinoconjunctivitis | Current eczema symptoms | Eczema ever | Symptoms of severe eczema |
| 13–14 years | HIC | 2015–20 | 11 | 35 459 | 4720 (13.3) | 6361 (17.6) | 1995 (5.6)# (42.3)¶ | 5483 (15.5) | 6953 (19.6) | 375 (1.0)# (6.8)¶ | 3521 (9.9) | 7364 (20.8) | 389 (1.1)# (11.0)¶ |
| UMIC | 2015–20 | 33 | 77 746 | 9132 (11.7) | 6832 (8.8)*** | 4376 (5.6) (47.9) | 11 056 (14.2) | 10 629 (13.7) | 717 (0.9) (6.5) | 4545 (5.8)*** | 4673 (6.0)**** | 791 (1.0) (17.4) | |
| LIC/LMIC | 2017–19 | 19 | 44 579 | 3587 (8.0)*** | 3400 (7.6)**** | 1911 (4.3) (53.3) | 4379 (9.8)** | 6423 (14.4) | 219 (0.5)*** (5.0) | 1971 (4.4)**** | 4619 (10.4)*** | 351 (0.8) (17.8) | |
| Total | 63 | 157 784 | 17 439 (11.1) | 16 593 (10.5) | 8282 (5.2) (47.5) | 20 918 (13.3) | 24 005 (15.2) | 1311 (0.8) (6.3) | 10 037 (6.4) | 16 656 (10.6) | 1531 (1.0) (15.3) | ||
| 6–7 years | HIC | 2016–19 | 8 | 23 040 | 2680 (11.6) | 3227 (14.0) | 1012 (4.4) (37.7) | 2346 (10.2) | 3501 (15.2) | 163 (0.7) (6.9) | 2334 (10.1) | 8234 (35.7) | 248 (1.1) (10.6) |
| UMIC | 2016–20 | 22 | 49 617 | 4984 (10.0) | 3310 (6.7)*** | 2360 (4.8) (47.3) | 4345 (8.8) | 5444 (11.0) | 334 (0.7) (7.7) | 2799 (5.6)**** | 3719 (6.6)**** | 313 (0.6)* (11.1) | |
| LIC/LMIC | 2017–19 | 14 | 29 120 | 1623 (5.6)**** | 1173 (4.0)**** | 621 (2.1)**** (38.3) | 1132 (3.9)**** | 2343 (8.0) | 86 (0.3)* (6.8) | 909 (3.1)**** | 1720 (5.9)**** | 116 (0.4)**** (12.8) | |
| Total | 44 | 101 777 | 9287 (9.1) | 7710 (7.6) | 3993 (3.9) (43.0) | 7823 (7.7) | 11 288 (11.1) | 583 (0.6) (7.6) | 6042 (5.9) | 13 673 (13.4) | 677 (0.7) (11.2) |
Data presented as n (%), unless otherwise indicated. GNI: gross national income; HIC: high income countries; UMIC: upper middle income countries; LIC/LMIC: low and lower middle income countries. #: total participants denominator; ¶: current symptoms (wheeze, rhinoconjunctivitis or eczema) denominator (see text for definitions). The base for comparisons was the group of HICs. *: p<0.05; **: p<0.01; ***: p<0.005; ****: p<0.001.